EP0804580B1 - Calciumbindende rekombinante antikörper gegen protein c - Google Patents

Calciumbindende rekombinante antikörper gegen protein c Download PDF

Info

Publication number
EP0804580B1
EP0804580B1 EP95923791A EP95923791A EP0804580B1 EP 0804580 B1 EP0804580 B1 EP 0804580B1 EP 95923791 A EP95923791 A EP 95923791A EP 95923791 A EP95923791 A EP 95923791A EP 0804580 B1 EP0804580 B1 EP 0804580B1
Authority
EP
European Patent Office
Prior art keywords
antibody
protein
sequence
hpc
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP95923791A
Other languages
English (en)
French (fr)
Other versions
EP0804580A1 (de
Inventor
Alireza Rezaie
Charles T. Esmon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/259,321 external-priority patent/US7247453B1/en
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Publication of EP0804580A1 publication Critical patent/EP0804580A1/de
Application granted granted Critical
Publication of EP0804580B1 publication Critical patent/EP0804580B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • This invention is generally in the area of antibodies to plasma proteins, specifically Protein C, and methods for use thereof.
  • Protein C is a vitamin K-dependent plasma protein zymogen to a serine protease. Upon activation it becomes a potent anticoagulant. Activated protein C acts through the specific proteolysis of the procoagulant cofactors, factor VIIIa and factor Va. This activity requires the presence of another vitamin K-dependent protein, protein S, calcium and a phospholipid (presumably cellular) surface. As described in Hemostasis and Thrombosis: Basic Principles and Clinical Practice 2nd Ed., Colman, R.W., et al.,p.
  • protein C circulates in a two-chain form, with the larger, heavy chain bound to the smaller light chain through a single disulfide link. A small proportion of the protein also circulates in a single chain form, where a Lys-Arg dipeptide in the molecule connects the light chain directly to the heavy chain.
  • Protein C is activated to activated protein C (APC).
  • APC activated protein C
  • Thrombin is capable of activating protein C by the specific cleavage of the Arg 12 -Leu 13 bond in the heavy chain.
  • the rate of this activation is enhanced dramatically when thrombin is bound to the endothelial cell cofactor, thrombomodulin.
  • Matschiner, et al. Current Advances in Vitamin K Research, pp. 135-140, John W. Suttie, ed. (Elsevier Science Publishing Co., Inc. 1988 ) have further reviewed the role of the Vitamin K dependent proteins in coagulation.
  • Protein C has been shown to have major importance in vivo. Patients deficient in protein C, or its cofactor, protein S, show pronounced thrombotic tendencies. Babies born totally deficient in protein C exhibit massive disseminated intravascular coagulation (DIC) and a necrotic syndrome which leads to death within the first few weeks of life if untreated. Activated protein C has also been shown to protect animals against the coagulopathic and lethal effects of endotoxin shock, as described by Taylor, et al., in J. Clin. Invest. 79, 918-925 (1987 ).
  • Protein C was originally isolated in semi-pure form from plasma using classic protein purification techniques, including barium citrate adsorption and elution, ammonium sulfate fractionation, DEAE-Sephadex chromatography, dextran sulfate agarose chromatography, and preparative polyacrylamide gel electrophoresis. This procedure was vastly improved and facilitated by the discovery of a unique antibody to Protein C, designated HPC-4, described by Stearns, et al., in J. Biol. Chem. 263(2), 826-832 (1988 ).
  • Protein C can be isolated from human plasma by batch adsorption of diluted heparinized plasma on QAE Sephadex, washing with buffered 0.15 M NaCl and eluting with 0.5 M NaCl, recalcifying and batch adsorbing with HPC-4, then washing with a Ca 2+ containing buffer and eluting the Protein C with an EDTA containing buffer.
  • HPC-4 is a calcium-dependent monoclonal antibody to human protein C.
  • HPC-4 is disclosed and claimed in U.S. Patent No. 5,202,253 to Esmon, et al.
  • WO 90/07524 describes a Ca 2+ dependent monoclonal antibody that specifically binds to a specific twelve peptide sequence (E D Q V D P R L I D G K) in the activation region of protein C.
  • Blockage of the natural anticoagulant pathways uses the natural procoagulant properties of the tumor to target the tumor capillaries for microvascular thrombosis, leading to hemorrhagic necrosis of the tumor, as described in U.S. Patent No. 5,147,638 to Esmon, et al .
  • HPC-4 is a preferred antibody for use in this method for the treatment of solid tumors, either alone or in conjunction with biological response modifiers, chemotherapy or radiation treatments.
  • Tumors contain proteins which predispose to the formation of blood clots in the vessels in the tumor bed. Tumors also contain other proteins and cellular elements which prevent thrombosis of tumor blood vessels. Tumor necrosis results from altering the hemostatic balance between procoagulant and anticoagulant mechanisms to favor thrombosis of the tumor microvasculature. The hemostatic balance of the tumor can be altered by blocking the conversion of protein C to its active form (activated protein C). The procoagulant mechanisms present in the tumor bed will then function without opposition and cause thrombosis of the tumor vessels.
  • the epitope for the HPC-4 antibody spans the activation site in protein C and as a result blocks protein C activation.
  • the antibody cross-reacts with protein C from canine, porcine and at least two primate plasmas, baboon and marmoset. It does not cross-react with bovine or mouse protein C.
  • the inhibitory effect can be reversed instantly by administration of activated protein C to which the antibody does not bind.
  • the antibody therefore provides a means to selectively inhibit the protein C pathway in vivo and to reverse the process if thrombotic complications ensue at sites other than the tumor.
  • the Protein C blocking agent is preferably administered in combination with a cytokine that stimulates natural killer and lymphokine-activated killer cell-mediated cytotoxicity, activates macrophages, stimulates Fc receptor expression on mononuclear cells and antibody-dependent cellular cytotoxicity, enhances HLA class II antigen expression, and/or stimulates procoagulant activity, such as tumor necrosis factor (TNF), interleukin-1 (IL-1), interleukin-2 (IL-2), gamma interferon (gamma-IFN), or granulocyte-macrophage colony stimulating factor (GMCSF).
  • TNF tumor necrosis factor
  • IL-1 interleukin-1
  • IL-2 interleukin-2
  • gamma-IFN gamma interferon
  • GMCSF granulocyte-macrophage colony stimulating factor
  • an agent such as endotoxin, or the purified liposaccharide (LPS) from a gram negative bacteria such as E .
  • HPC-4 despite its wonderful properties, is a murine antibody. It would be advantageous to be able to provide a humanized form of the antibody which is non-immunogenic or less immunogenic. In order to construct a humanized form of HPC-4 it is essential to know the sequence of the hypervariable regions of this antibody. Then using conventional mutagenesis methods developed in molecular biology it is possible to replace the sequence of hypervariable regions of an unrelated human antibody with the sequences of HPC-4 hypervariable regions. Such an approach has been successfully used in the humanization of other antibodies.
  • the amino acid and nucleic acid sequences of the hypervariable regions of the HPC-4 antibody have been determined and used in the construction of "humanized antibodies”. Peptides derived from the hypervariable regions are also disclosed which are useful in mimicking HPC-4 - protein C binding. These materials are useful in isolation of protein C, treatment of tumor patients, and as inhibitors of coagulation, as well as in diagnostic assays.
  • the present invention relates to a recombinant Ca 2+ dependent monoclonal antibody as Fab as defined in claim 1.
  • the antibody does not bind to activated protein C (“APC”) and can be used to inhibit activation of Protein C by thrombin-thrombomodulin.
  • APC activated protein C
  • the Fab (fragment antigen binding) sequence of the HPC-4 antibody was constructed in a bacterial periplasmic expression vector and the recombinant antibody was isolated from bacterial cell culture supernatants in large quantities by affinity chromatography using the peptide sequence described above bound to an immobilized substrate.
  • the antibody has a number of specific uses in isolation and characterization of Protein C, as a diagnostic, and as a therapeutic to prevent activation of Protein C. In vivo, a humanized recombinant antibody has been demonstrated to inhibit tumor growth. Further, the antibody is effective in promoting clotting in patients having high levels of Factor VIII inhibitors, hemophilia, platelet deficiencies (thrombocytopenia), and other clotting disorders where it is desirable to increase clotting.
  • Antibodies are large proteins (approximately 150,000 daltons in the case of an immunoglobulin G), that consist of four polypeptide chains: two identical heavy chains and two identical light chains.
  • the antigen-binding site consists of roughly the first 110 amino acids of the heavy and light chains, and is termed the variable region.
  • Antibodies bind molecules with association constants that range from 10 4 to 10 14 M -1 . Small molecules, typically from 100 to 2500 Daltons, are typically bound in the cleft of the antibody molecule, but for large molecules, for example, from 10 KDa to 500 KDa, the binding site can be an extended surface that can cover 600 to 800 ⁇ . The specificity of antibodies for their ligands can exceed that of enzymes for substrates.
  • Recombinant antibodies are constructed that typically consist of the hypervariable regions of the heavy and light chains of the antibody from which the sequence is derived, in this case HPC-4, which may be crosslinked or coupled to other antibody domains or fusion proteins as discussed in more detail below.
  • the antibody can be modified by site directed mutagenesis of the coding sequence, commonly used in molecular biology to alter affinity or specificity, as well as humanized to improve in vivo utility.
  • the antibody binds protein C, not activated protein C (APC), and only in the presence of calcium.
  • protein C can be isolated from either plasma-derived sources or from tissue culture expression systems under extremely mild conditions. This is important in maintaining the biological activity of the product and the stability of the solid support resin. Since activated protein C is not bound under any conditions, the resulting product is completely free of APC.
  • the antibody binds to the activation site on protein C and can therefore be used to block the formation of the anticoagulant protein APC in vivo. Since it does not bind to or inhibit APC, the in vivo inhibitory effects can be reversed by administration of APC.
  • RNA from approximately 1 x 10 8 HPC-4 hybridoma cells grown in 75 ml T-flasks was prepared and mRNA (PolyA + RNA) was isolated on oligo(dT)-cellulose according to the manufacturer's instruction (Stratagene, CA). Approximately 10 ⁇ g of PolyA + RNA was used to synthesize first and then second-strand cDNA according to established procedures. Using standard molecular biology techniques, EcoRI linkers were ligated to double stranded cDNA (ds cDNA) and the ds cDNA ligated to phage lambda (lambda gt10) vector DNA which has been digested with EcoRI.
  • ds cDNA double stranded cDNA
  • phage lambda phage lambda
  • HPC-4 cDNA and lambda gt10 phage vector ligation mixture was packaged in vitro and transformed into C600hflA strain of E . coli, and plated onto agar plates at high density. The bacteriophage plaques were then transferred to Gene Screen Plus TM filters (New England Nuclear) and probed with 32 P labeled cDNA fragments derived from constant regions of an unrelated immunoglobulin heavy chain ( Tasuku Honjo et al, Cell 18:559-568, 1979 ) and light chain genes ( Edward Max et al, J. Biol. Chem. 256:5116-5120, 1981 ).
  • variable regions of heavy (VH) and light chain (VL) of HPC-4 monoclonal antibody were cloned by the PCR method as well.
  • poly(dG) tail was added to the 3' end of first strand with terminal deoxynucleotidyl transferase (TdT).
  • TdT terminal deoxynucleotidyl transferase
  • the antisense primer derived from the 3' end of the heavy chain constant region 5'-AAGCGGCCGCTGGATAGACAGATGGGGGTGTCGTTTTGCC-3' (Sequence ID No.
  • HPC-4 Fab fragment antigen binding sequence of HPC-4 was amplified from the heavy and light chain cDNA by the PCR methods for expression as outlined briefly below:
  • the Fab region of an antibody is made of VH and the constant heavy chain domain 1 (CH1) held together with VL and the constant light chain (CL).
  • the heavy chain forward primer was 5'-AGGTTACTCTGCTCGAGTCTGGCCCTGG-3' (Sequence ID No. 5) which was designed to have a XhoI restriction enzyme site for construction purposes.
  • the heavy chain reverse primer (complementary to the 3' end of CH1 region) 5'-AGGCCTACTAGTTTACTAACAATCCCTGGGCACAAT-3' (Sequence ID No. 6) was synthesized with two stop codons and an SpeI site after the stop codons.
  • a light chain forward primer 5'-TGTCCAGAGGAGAGCTCATTCTCACCCAGTCTCCGGC-3' (Sequence ID No. 7) was synthesized which contained a SacI restriction enzyme site and the reverse primer 5'-TCCTTCTAGATTACTAACACTCTCCCCTGTTGAA-3' (Sequence ID No. 8) contained two stop codons and an XbaI site for construction purposes.
  • the heavy and light chain HPC-4 cDNA were amplified by these primers and the resulting DNA fragments were subcloned into Immuno ZAP H TM and Immuno ZAP L TM vectors, respectively, according to the manufacturer's instruction (Stratagene, CA).
  • HPC-4 Fab was expressed in the periplasmic space of bacteria (XL1-B strain of E.Coli) and purified on its own 12 residue epitope from human protein C activation peptide region (Glu-Asp-Gln-Val-Asp-Pro-Arg-Leu-Ila-Asp-Gly-Lys (Sequence ID No. 1), linked to Affigel TM .
  • the HPC-4 Fab was eluted with TBS (20 mM Tris HCl, pH 7.5, 0.1 M NaCl) containing 5 mM EDTA, indicating that the binding of Fab fragment of HPC-4 to its epitope, like the full length native HPC-4 antibody, is Ca 2+ dependent.
  • the mature peptide starts at amino acid 23 which is a Q.
  • DNA sequences would code for the polypeptide antibody fragments described above. This is due to existence of the degeneracy of the genetic code, which means that different codons (sets of three bases) can code for the same amino acid residue. These are known to those skilled in the art. It is also possible to synthesize DNA sequence having different additional substitution than those described above but which would still code for a protein having the same binding specifications, for example, which has conservative amino acid substitutions, i.e., substitutions of one amino acid with another of similar size and charge.
  • recombinant antibodies can be constructed using known methodology. Methods for constructing chimeric genes have been described by, for example, Kobilka, B.K., et al, "Chimeric ⁇ 2-, ⁇ 2-Adrenergic Receptors: Delineation of Domains Involved in Effector Coupling and Ligand Binding Specificity" Science 240:1310-1316, 1988 ; Verhoeyen, M., C. Milstein, G. Winter, "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," Science, 239:1534-1536, 1988 ; Riechmann,L., M. Clark, H Waldmann, G.
  • the target DNA, containing the gene for the monoclonal antibody of interest can be constructed into appropriate expression vectors, such as baculovirus expression vectors, according to the procedures described in Summers, M.D. and G.E. Smith, "A manual of methods for baculovirus vectors and insect cell culture procedures", Texas Agricultural Experimental Station (1987). Expression of the recombinant gene can be achieved by the methods described therein, the teachings of which are incorporated herein. Alternatively, recombinant antibodies can be produced in bacterial periplasmic expression vectors such as those described above. Screening for the desired product can be achieved by ELISA assay wherein released protein is tested for its ability to recognize the antigen for which the target immunoglobulin was specific in a metal dependent manner.
  • a humanized antibody is one in which only the antigen-recognizing sites, or complementarity-determining hypervariable regions (CDRs) are of non-human origin, whereas all other regions including the framework regions (FRs) of variable domains are products of human genes.
  • CDRs complementarity-determining hypervariable regions
  • FRs framework regions
  • animal CDRs are distinguished from animal framework regions (FRs) based on locations of the CDRs in known sequences of animal variable genes, ( Kabat, H.A., et al., Sequences of Proteins of Immunological Interest, 4th Ed. U.S. Dept. Health and Human Services, Bethesda, MD, 1987 ).
  • FRs animal framework regions
  • the animal CDRs and FRs are grafted onto the sequence of an unrelated human heavy and light chain variable region frameworks by the standard molecular biology techniques including the use of synthetic oligonucleotides and polymerase chain reaction (PCR) methods.
  • the entire sequences of a known human variable heavy and light chain gene in which all the codons encoding for the CDRs are replaced with the desired CDRs of animal antibody are synthesized in the laboratory by a DNA synthesizer (Applied Biosystems Division of Perkin-Elmer Cetus, CA).
  • the resulting synthetic DNA sequences encoding for the human heavy and light chain variable regions with grafted CDRs from animal antibody are subcloned into expression vectors and recombinant fusion antibodies are prepared in baculovirus or periplasmic space of bacteria as described above. Recombinant antibodies can be produced in mammalian expression systems as well.
  • the immunogenic stimulus presented by the monoclonal antibodies so produced may be also decreased by the use of Pharmacia's (Pharmacia LKB Biotechnology, Sweden) "Recombinant Phage Antibody System” (RPAS), which generates a single-chain Fv fragment (ScFv) which incorporates the complete antigen-binding domain of the antibody.
  • RPAS Recombinant Phage Antibody System
  • the variable heavy and light chain genes are separately amplified from the hybridoma mRNA and cloned into an expression vector.
  • the heavy and light chain domains are co-expressed on the same polypeptide chain after joining with a short linker DNA which codes for a flexible peptide.
  • ScFv single-chain Fv fragment
  • HPC-4 from ascites and the recombinant HPC-4 bind to a defined region of the protein C molecule that is contained within residues 6 and 17 of the heavy chain, specifically E D Q V D P R L I D G K (Sequence ID No. 1).
  • This peptide can be immobilized directly on a solid support resin and can be used to isolate the antibody in high concentrations from ascites fluid or as recombinant form from cell culture supernatants. This approach allows the isolation of the antibody in extremely pure form in high yield, even from very dilute solutions.
  • the antibody can be removed from the solid support peptide either by the removal of calcium ions, if desired, or by 1.5 M guanidine, which does not affect the function of the purified monoclonal antibody. This may be significant, as guanidine is recognized as a viral deactivation agent by regulatory agencies. After elution or treatment with this agent, the antibody will not contain any live virus which may be present either in the ascites fluid derived from the mice used to produce the monoclonal antibody or culture supernatants, if tissue culture for production of recombinant antibody was used. Accordingly, virus will not be introduced into the protein C product from the antibody used to prepare it.
  • the peptide is coupled to Affi-Gel TM 15 to give a final concentration of approximately 1.0 mg/ml.
  • Coupling of the epitope peptide is performed in 0.1 M NaCl, 0.1 M MOPS, pH 7.5, at 4°C as described by the manufacturer (Bio-Rad, Richmond, CA).
  • the Affi-Gel TM is washed with ice cold water immediately before use to remove the organic solvent.
  • the epitope peptide is prepared at a concentration of between 1 and 2 mg/ml in 0.1 M NaCl, 0.1 M MOPS, pH 7.5, and mixed with sufficient Affi-Gel TM 15 to give a final ratio of peptide to gel of 1 mg/ml.
  • the peptide and the gel are mixed overnight (between approximately 12 and 18 h) on a gentle rocker to couple the peptide to the gel.
  • the resin is poured into a glass column, and washed with 0.1 M NaCl 0.01 M MOPS, pH 7.5. 100 ml of resin has a capacity of at least 1.5 grams of HPC-4.
  • Human protein C can be coupled to the Affi-Gel TM by the same method. Three to five mg protein C/ml of the buffer described above is mixed with sufficient Affi-Gel TM 15 to give a final ratio of human protein C to gel of 3-5 mg protein/ml of gel.
  • the desalted ammonium sulfate fraction from the ascites is loaded onto the epitope affinity column, and the column is washed with at least 4 column volumes of 0.4 M NaCl, 0.02 M Tris HCl, 1 mM CaCl 2 , pH 7.5.
  • the HPC-4 or recombinant antibody is then eluted from the column in one of the following ways: (1) 2 M NaCl, 0.02 M Tris HCl, 2 mM EDTA; (2) 2 M NaCl, 1.5 M guanidine HCl, 0.02 M Tris HCl, 2 mM EDTA.
  • the advantage of the latter is that the protein elutes as a much sharper peak, with concentrations of greater than 25 mg/ml when 200 ml of ascites is applied to a 100 ml column of resin.
  • the antibody retains greater than 95% of the capacity to bind to the epitope after elution under these conditions.
  • Antibody is then either dialyzed or desalted into the appropriate buffer for further applications. No contaminants of the antibody are detectable by SDS gel electrophoresis. Additional antibody can be obtained by applying the breakthrough material back to the column if the column is overloaded above its capacity.
  • HPC-4 The recombinant antibody can be utilized in the same way as HPC-4 for purification and therapeutic purposes.
  • HPC-4 includes both the deposited murine monoclonal antibody and recombinant forms thereof.
  • Antibody and the gel are mixed overnight (12-18 h) on a gentle rocker to allow the coupling reaction. Usually greater than 90% of the antibody is bound.
  • the resin is poured into a glass column, and washed with 0.1 M NaCl 0.01 M MOPS, pH 7.5. The resin is stable at 4°C under these conditions for at least one year. 100 ml of resin has a capacity of at least 20 milligrams of protein C.
  • the peptide can be used in the isolation and purification of HPC-4 by affinity chromatography.
  • the peptide can be used to temporarily "protect" the binding site during the process in which the antibody is bound to the chromatography substrate, to insure that the maximum amount of bound antibody is available for binding to the protein to be isolated.
  • the reactive groups of the peptide which are capable of reacting with the chromatography substrate (amino terminal, lysine side chain), which are not required for recognition by HPC-4, are first blocked by reaction of the peptide with acetic anhydride using standard methods known to those skilled in the art. After the HPC-4 is coupled to the resin, the peptide bound in the antigen binding site of the antibody is removed by washing the resin with 1.5 M Guanidine HCl, 2 mM EDTA, 0.02 M Tris HCl, pH 7.5.
  • the antibody and peptide can be bound to a variety of substrates, for use in purification and isolation of Protein C and the antibody, respectively, including agarose, acrylamide and other types of conventional chromatographic resins, filters, etc. These materials are known to those skilled in the art, as are the methods for attaching the protein to them. The selection of the material will depend in large part on the scale of the purification or the sample to be analyzed, as well as biocompatibility and government agency approval where the end-product is for pharmaceutical use.
  • Methods and means for labeling the antibody for use as a diagnostic are known to those skilled in the art, including labelling with a radioactive, fluorescent, luminescent, or enzymatic molecule.
  • the antibodies are then used in diagnostic assays to measure the amount of Protein C rather than Activated Protein C or total Protein C, since the antibody does not bind Activated Protein C, unlike other antibodies to Protein C.
  • a fusion protein readily isolated by affinity chromatography using HPC-4 antibody is prepared by insertion of a DNA sequence encoding the twelve amino acid HPC-4 epitope into a vector, followed by the gene encoding the protein to be isolated as described in U.S. Patent No. 5,298,599 issued March 29, 1994 .
  • a specific protease cleavage site is inserted into the vector between the epitope and protein coding sequence, so that the resulting fusion protein can be easily cleaved to yield the epitope peptide and the desired protein.
  • the fusion protein includes a protease cleavage site between the epitope and the protein to be isolated.
  • Suitable sites include sequences cleaved by Factor Xa: Ile Glu Gly Arg (IEGR), enterokinase: Asp Asp Asp Asp Lys (DDDDK), and thrombin: Phe/Gly Pro Arg (F/GPR).
  • IEGR Ile Glu Gly Arg
  • DDDDK enterokinase
  • F/GPR thrombin
  • the coagulant and anticoagulant systems in mammals provide a delicate check and balance system which maintains blood in its proper fluid state. Alteration of any single element in this system can have an enormous impact on the ability of the mammal to maintain hemostasis.
  • the protein C system is an anticoagulant, regulatory system which inhibits blood coagulation and stimulates fibrinolysis.
  • This system is activated by thrombin, an enzyme which converts fibrinogen to fibrin in the coagulative process. Free or excess thrombin binds with thrombomodulin, a protein on endothelial cells.
  • the thrombin-thrombomodulin complex abolishes the ability of thrombin to catalyze clot formation and converts thrombin into a potent protein C activator.
  • Activated Protein C in turn acts in combination with Protein S and a membrane surface to inactivate factor Va and factor VIIIa by limited proteolysis.
  • the inactivated factor Va loses the ability to interact effectively with the enzyme factor Xa or the substrate prothrombin.
  • Addition of an antibody to Protein C, an antibody to Protein S, or addition of C4b binding protein (C4bBP), which binds Protein S to thereby inactivate it as a cofactor, in an appropriate form, can be used to promote clotting in individuals where it is desirable to do so.
  • Patients having factor VIII inhibitors are representative of this group of patients. By preventing the factor Va from being inactivated, coagulation proceeds even in the relative absence of factor VIII.
  • This method can also be applied in the treatment of other clotting factor deficiency states, including thrombocytopenia, for example, as induced by heparin or radiation therapy, liver disease and hemorrhagic stroke, both acutely and to minimize re-bleeding after the acute incident.
  • thrombocytopenia for example, as induced by heparin or radiation therapy, liver disease and hemorrhagic stroke, both acutely and to minimize re-bleeding after the acute incident.
  • HPC-4 can also be used to induce microvascular clotting in a solid tumor bed, as described in U.S. Patent No. 5,147,638 issued September 5, 1992 . In animal tumor models, this has been found to greatly impede growth of the tumor.
  • the combination of this antibody and/or the other agents indicated above which are capable of blocking the function of the protein C anticoagulant pathway with other treatments presently in use, such as tumor necrosis factor or radiation, can also be used for treatment of solid tumors.
  • Pharmaceutically acceptable carriers for administration of the antibodies include sterile normal saline at physiological pH.
  • the agent is injected into the subject, most preferably, intravenously.
  • Preferred dosages are between about 30 and about 150 ⁇ g antibody/ml patient plasma, which is sufficient to block greater than 90% of the endogenous protein C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (13)

  1. Rekombinanter Ca2+-abhängiger monoklonaler Antikörper oder Fab, die mit einem Epitop in der Aktivierungspeptidregion der schweren Kette von Protein C, das durch E D Q V D P R L I D G K (Sequenz ID No. 1) definiert ist, in Kombination mit Calcium immunreaktiv sind, wobei der Antikörper die Protein-C-Aktivierung durch Thrombin-Thrombomodulin hemmt, wobei der Antikörper oder das Fab eine humane Aminosäuresequenz enthält, wobei der Antikörper oder das Fab eine Aminosäuresequenz umfasst, die aus der Gruppe von:
    Figure imgb0017
    ausgewählt ist oder eine oder mehrere konservative Substitutionen der angegebenen Aminosäuresequenz aufweist, wobei die Bindung des Antikörpers oder Fab an das Epitop calciumabhängig ist.
  2. Antikörper nach Anspruch 1, der zum Teil durch eine Nucleotidsequenz, die aus der Gruppe von
    Figure imgb0018
    Figure imgb0019
    und degenerierten Sequenzen derselben ausgewählt ist, codiert wird.
  3. Antikörper nach Anspruch 1, der ferner einen pharmazeutisch akzeptablen Träger zur Verabreichung an einen Patienten umfasst.
  4. Antikörper nach Anspruch 3, der ferner ein Cytokin oder einen Induktor der Cytokinexpression in einer in Kombination mit dem Antikörper zur Koagulation der Mikrovaskulatur in Tumoren, jedoch nicht in Abwesenheit des Antikörpers wirksamen Dosis umfasst.
  5. Antikörper nach Anspruch 1, der eine an den Antikörper gebundene detektierbare Markierung aufweist.
  6. Antikörper nach Anspruch 1, der an einem Substrat immobilisiert ist, wobei der immobilisierte Antikörper zur Reinigung von Protein C aus einer biologischen Flüssigkeit geeignet ist.
  7. Verwendung eines rekombinanten Ca2+-abhängigen monoklonalen Antikörpers gemäß der Definition in einem der Ansprüche 1 bis 3 bei der Herstellung eines Medikaments zur Behandlung, eines Patienten, der eine Hemmung des Protein-C-Antikoagulantiums benötigt.
  8. Verwendung nach Anspruch 7, wobei das Medikament zur Behandlung eines Patienten, dem ein Cytokin oder ein anderes Chemotherapeutikum verabreicht wird, in einer zur Koagulation der Mikrovaskulatur eines Tumors wirksamen Menge dient.
  9. In-vitro-Verfahren zur Herstellung eines rekombinanten Ca2+-abhängigen monoklonalen Antikörpers gemäß der Definition nach Anspruch 1 durch Expression einer für den Antikörper codierenden Nucleotidsequenz.
  10. Verfahren nach Anspruch 9, wobei der Antikörper zum Teil durch eine Nucleotidsequenz, die aus der Gruppe von
    Figure imgb0020
    Figure imgb0021
    und degenerierten Sequenzen derselben ausgewählt ist, codiert wird.
  11. Verfahren nach Anspruch 9, das ferner die Bindung einer detektierbaren Markierung an den Antikörper umfasst.
  12. Verfahren nach Anspruch 9, das ferner das Immobilisieren des Antikörpers an einem Substrat umfasst, wobei der immobilisierte Antikörper zur Reinigung von Protein C aus einer biologischen Flüssigkeit geeignet ist.
  13. Antikörper nach einem der Ansprüche 1 bis 4 zur Verwendung in der Medizin.
EP95923791A 1994-06-10 1995-06-09 Calciumbindende rekombinante antikörper gegen protein c Expired - Lifetime EP0804580B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/259,321 US7247453B1 (en) 1988-12-30 1994-06-10 Calcium binding recombinant antibody against protein C
US259321 1994-06-10
PCT/US1995/007372 WO1995034652A1 (en) 1994-06-10 1995-06-09 Calcium binding recombinant antibody against protein c

Publications (2)

Publication Number Publication Date
EP0804580A1 EP0804580A1 (de) 1997-11-05
EP0804580B1 true EP0804580B1 (de) 2008-10-08

Family

ID=22984456

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95923791A Expired - Lifetime EP0804580B1 (de) 1994-06-10 1995-06-09 Calciumbindende rekombinante antikörper gegen protein c

Country Status (7)

Country Link
EP (1) EP0804580B1 (de)
JP (1) JPH10504186A (de)
AT (1) ATE410514T1 (de)
AU (1) AU710106B2 (de)
CA (1) CA2192467C (de)
DE (1) DE69535855D1 (de)
WO (1) WO1995034652A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750126B2 (en) 1998-04-14 2010-07-06 Chugai Seiyaku Kabushiki Kaisha Antibodies that bind to a member of the IL-6/G-CSF/MGF family

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200407335A (en) 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
EP2765192A4 (de) * 2011-10-05 2015-04-15 Chugai Pharmaceutical Co Ltd Antigenbindendes molekül zur herstellung eines abstands zwischen einem plasma und einem antigen mit einer saccharidkettenrezeptor-bindenden domäne
PL3462173T3 (pl) 2012-08-21 2021-08-16 Janssen Pharmaceutica Nv Przeciwciała przeciwko rysperydonowi i ich zastosowanie
EP2888277A4 (de) 2012-08-21 2016-05-18 Ortho Clinical Diagnostics Inc Antikörper gegen paliperidon und verwendung davon
CN106928369B (zh) 2012-08-21 2021-04-02 奥索临床诊断有限公司 喹硫平的抗体及其用途
JP6270845B2 (ja) 2012-08-21 2018-01-31 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールに対する抗体及びその使用
CN104736567B (zh) 2012-08-21 2019-09-03 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
CN104736566A (zh) 2012-08-21 2015-06-24 奥索临床诊断有限公司 帕潘立酮半抗原的抗体及其用途
PT2887952T (pt) 2012-08-21 2019-08-30 Janssen Pharmaceutica Nv Anticorpos para haptenos da olanzapina e suas utilizações
WO2014031584A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of aripiprazole and their use in immunoassays
PL2888284T3 (pl) 2012-08-21 2023-02-27 Janssen Pharmaceutica Nv Przeciwciała przeciwko haptenom rysperydonu i ich zastosowanie
EP2888590B1 (de) 2012-08-21 2020-07-08 Janssen Pharmaceutica NV Antikörper gegen olanzapin und verwendung davon
ES2664952T3 (es) 2012-08-21 2018-04-24 Janssen Pharmaceutica Nv Anticuerpos para haptenos de quetiapina y uso de los mismos
EP3047857A4 (de) * 2013-09-20 2017-08-09 Chugai Seiyaku Kabushiki Kaisha Behandlung von hämorrhagischen erkrankungen durch anti-protein-c-antikörper
EP3390455A1 (de) 2015-12-17 2018-10-24 Janssen Pharmaceutica NV Antikörper gegen quetiapin und verwendung davon
EP3390449A1 (de) 2015-12-17 2018-10-24 Janssen Pharmaceutica N.V. Antikörper gegen risperidon und verwendung davon

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2006684C (en) * 1988-12-30 1996-12-17 Charles T. Esmon Monoclonal antibody against protein c
US5147638A (en) * 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
AU4784693A (en) * 1992-07-24 1994-02-14 Oklahoma Medical Research Foundation Blockade of protein c activation reduces microvascular surgical blood loss

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STEARNEST D.J. ET AL, THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 263, no. 2, 1988, pages 826 - 832 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750126B2 (en) 1998-04-14 2010-07-06 Chugai Seiyaku Kabushiki Kaisha Antibodies that bind to a member of the IL-6/G-CSF/MGF family

Also Published As

Publication number Publication date
ATE410514T1 (de) 2008-10-15
DE69535855D1 (de) 2008-11-20
EP0804580A1 (de) 1997-11-05
AU2822995A (en) 1996-01-05
WO1995034652A1 (en) 1995-12-21
JPH10504186A (ja) 1998-04-28
AU710106B2 (en) 1999-09-16
CA2192467A1 (en) 1995-12-21
CA2192467C (en) 2009-03-31

Similar Documents

Publication Publication Date Title
EP0804580B1 (de) Calciumbindende rekombinante antikörper gegen protein c
CA2045869C (en) Fusion proteins with immunoglobulin portions, the preparation and use thereof
Gillies et al. Biological activity and in vivo clearance of anti-tumor antibody/cytokine fusion proteins
JP4237711B2 (ja) 新規ｐ−セレクチンリガンド蛋白
JPH07504812A (ja) 細胞付着を促進するための新規なポリペプチド
EP0753065A1 (de) Antikörper gegen e-selektin
US5260274A (en) Factor VIII binding domain of von Willebrand Factor
WO2001016321A1 (en) Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
CZ305602B6 (cs) Polypeptidická proteáza štěpící von Willebrandův faktor (vWF), nukleová kyselina kódující tento polypeptid a použití tohoto polypeptidu
AU641634B2 (en) Monoclonal antibody against protein C
IL141158A (en) Human immunoglobulin that binds to the human willybrand factor
AU781618C (en) FVIIa antagonists
JPH10501813A (ja) 腫瘍処置のための組成物および方法
KR100240159B1 (ko) 당단백질 gpiib/iiia와 반응성인 사람화된 면역글로불린
US7247453B1 (en) Calcium binding recombinant antibody against protein C
US5773228A (en) Activation-dependent protein expressed on the surface of activated platelets and antibodies thereto
WO1994025491A1 (en) Fibrin-targeted inhibitors of thrombin
AU755574B2 (en) Synthetic peptide immunogens and antibodies thereto
WO1993011778A1 (en) Bifunctional antithrombotic molecules and antithrombotic polypeptides
WO1992017192A1 (en) Therapeutic fragments of von willebrand factor
WO1999060405A1 (en) Method for diagnosis and treatment of cancer
WO2004064709A2 (en) Thrombolytic agent
JPH05219957A (ja) 組織因子誘導体
IE84574B1 (en) Fusion proteins with parts of immunoglobulins, their production and use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970110

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030110

17Q First examination report despatched

Effective date: 20030110

17Q First examination report despatched

Effective date: 20030110

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/19 20060101ALI20080331BHEP

Ipc: A61K 33/06 20060101ALI20080331BHEP

Ipc: A61K 39/395 20060101ALI20080331BHEP

Ipc: C07K 17/00 20060101ALI20080331BHEP

Ipc: C07K 16/46 20060101ALI20080331BHEP

Ipc: C07K 16/40 20060101ALI20080331BHEP

Ipc: C12N 15/13 20060101AFI20080331BHEP

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69535855

Country of ref document: DE

Date of ref document: 20081120

Kind code of ref document: P

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090119

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081008

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090217

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081008

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081008

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081008

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090108

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081008

26N No opposition filed

Effective date: 20090709

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090630

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20090609

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20100226

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090630

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090609

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090630

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090609

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090109

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090609